FDA grants Orphan Drug Designation for NNZ-2591 to treat Phelan-McDermid syndrome and Pitt Hopkins syndrome
16 October Melbourne, Australia: Neuren Pharmaceuticals (ASX: NEU) today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Neuren’s NNZ-2591 for the treatment of each of Phelan-McDermid syndrome and Pitt Hopkins syndrome.…
CSIROscope: How do you mend a broken heart?
16 October 2019 By Ali Green Sunday was World Heart Day and we celebrated in true CSIRO style – with science and technology. In a world-first, a man in the US received a replacement heart valve. It was…
ASX Health Care & Biotechnology CEO reported remuneration continues to decline for FY2019
16 October 2019 By Lee Rochester, Managing Partner, Wexford Hayes Executive Search & Board Advisory With Chief Executive remuneration constantly in the spotlight and being one of the more complex issues that boards are required to manage Wexford Hayes…
Bionics Institute receives comprehensive ISO 9001 accreditation covering all operations, research and development processes
16 October 2019 The Bionics Institute is the first and only Australian Medical Research Institute (MRI) to receive a comprehensive ISO 9001 accreditation covering all operations, research and development processes. This accreditation reinforces the Bionics Institutes commitment to…
Immutep Reports Positive Final Efficacy Data from TACTI-mel Trial in Melanoma
15 October 2019 SYDNEY, AUSTRALIA – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today announces mature positive efficacy data from its TACTI-mel Phase…
Tim Oldham Appointed as Chief Executive Officer of AdAlta Ltd
9.10.2019 MELBOURNE Australia: The Board of AdAlta Limited (ASX:1AD), is pleased to announce the appointment of experienced global pharmaceutical executive Dr Tim Oldham as Chief Executive Officer and Managing Director. Dr Oldham has extensive skills and expertise over…
Smileyscope secures a prominent Silicon Valley investor
9 October 2019 August and September have been landmark months for Smileyscope. We welcome our largest investor to date, and are closing a funding round which will allow us to grow rapidly through the next 18 months. Our…
Opthea To Present at the Ophthalmology Innovation Summit in San Francisco
4 October 2019 Melbourne, Australia – Opthea Limited (ASX:OPT), a clinical-stage biopharmaceutical company developing novel biologic therapies to treat back-of-the-eye diseases, announced today that Dr Megan Baldwin, the Company’s Chief Executive Officer, will present at the Ophthalmology Innovation…
Cartherics Pty Ltd to Present at 2019 Cell & Gene Meeting on the Mesa
1 October 2019 Melbourne, Australia, – Cartherics Pty Ltd announced today that Professor Richard Boyd, Chief Scientific Officer, will present at the annual Cell & Gene Meeting on the Mesa to be held October 2-4 in Carlsbad, California.…
Immutep Announces Expansion of Part A of TACTI-002 Phase II Clinical Trial due to Positive Interim Data
26 September 2019 • Requisite clinical responses achieved in cohort 1 of Part A (1st line NSCLC) of TACTI-002 Phase II clinical trial to allow for recruitment of cohort 2 • Recruitment of cohort 2 of Part A…
Opthea Receives A$14.6m R&D Tax Incentive
1 October, 2019 Melbourne, Australia – Opthea Limited (ASX:OPT), a clinical-stage biopharmaceutical company developing novel biologic therapies to treat back-of-the-eye diseases, announced today it received a A$14.6 million research and development (R&D) tax credit from the Australian Taxation…
Medical Device Partnering Program (MDPP Victoria) drop-in sessions
11 September 2019 Calling all Victorian-based stakeholders! Keep an eye out as the Medical Device Partnering Program (MDPP) will be in your neighbourhood! Drop-In sessions will run for the next few weeks as part of our ongoing strategy to…
